EpiCept Recieves A De-Listing Warning from Nasdaq, To Open Lower On Monday
Back in the first week of September EpCept (EPCT) stock plunged more than 30% as its phase 3 trial of LidoPAIN, a lidocaine analgesic patch to be worn by post operative patients, did not meet co-primary end point.
Then, just this past Friday, September the 22nd, the company announced that it had recieved a Listing Defeciency Notification because it did not comply with some listing requirements, including not having a minimum market cap of $50 million for ten consecutive days.
As investors in the company had experienced before, the stock should open lower on Monday, as the delisting warning was announced by EpiCept after market close, of course!
_
Back in the first week of September EpCept (EPCT) stock plunged more than 30% as its phase 3 trial of LidoPAIN, a lidocaine analgesic patch to be worn by post operative patients, did not meet co-primary end point.
Then, just this past Friday, September the 22nd, the company announced that it had recieved a Listing Defeciency Notification because it did not comply with some listing requirements, including not having a minimum market cap of $50 million for ten consecutive days.
As investors in the company had experienced before, the stock should open lower on Monday, as the delisting warning was announced by EpiCept after market close, of course!
_
posted by Nico at
4:55 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home